CRBU: Caribou Biosciences, Inc.
About
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
Current Value
$1.981 Year Return
Current Value
$1.981 Year Return
Key Details
Market Cap
$179.29M
P/E Ratio
-1.2
1Y Stock Return
-65.20%
1Y Revenue Growth
-66.85%
Dividend Yield
0.00%
Price to Book
0.6
Strategies that include CRBU
Stock's related to CRBU
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ALLO | 55.90% | $442.41M | -22.43% | 0.00% |
| GRAL | 53.51% | $508.58M | -3.65% | 0.00% |
| BEAM | 52.50% | $1.95B | -19.99% | 0.00% |
| FATE | 51.24% | $235.76M | -13.39% | 0.00% |
| NTLA | 48.92% | $1.41B | -54.40% | 0.00% |
| MBC | 48.92% | $2.12B | +24.24% | 0.00% |
| ABCL | 48.34% | $803.40M | -38.60% | 0.00% |
| CRSP | 48.15% | $3.95B | -34.33% | 0.00% |
| OPEN | 47.18% | $1.22B | -30.61% | 0.00% |
| ARVN | 47.18% | $1.73B | +17.28% | 0.00% |
| EDIT | 47.17% | $195.64M | -77.41% | 0.00% |
| VRDN | 46.76% | $1.55B | +25.13% | 0.00% |
| ALEC | 46.60% | $368.23M | -22.31% | 0.00% |
| ADPT | 45.49% | $644.92M | +2.82% | 0.00% |
| TWST | 44.13% | $2.44B | +74.97% | 0.00% |
| TXG | 44.11% | $1.61B | -69.34% | 0.00% |
| MGTX | 44.04% | $462.67M | +9.43% | 0.00% |
| PACB | 43.88% | $484.74M | -78.83% | 0.00% |
| VCYT | 43.82% | $3.02B | +49.08% | 0.00% |
| YORW | 43.51% | $509.85M | -5.84% | 2.38% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LNG | -0.03% | $50.48B | +26.56% | 0.81% |
| KNOP | 0.06% | $211.76M | +11.07% | 1.69% |
| ALAR | 0.08% | $91.57M | +144.30% | 0.00% |
| CME | 0.11% | $81.64B | +7.34% | 2.00% |
| XNET | 0.12% | $117.91M | +20.78% | 0.00% |
| STNG | -0.13% | $2.81B | -6.67% | 2.97% |
| CPB | 0.13% | $13.23B | +8.54% | 3.29% |
| NERV | -0.15% | $15.46M | -55.98% | 0.00% |
| PRPO | -0.29% | $8.89M | -14.59% | 0.00% |
| AIZ | 0.31% | $11.55B | +37.38% | 1.28% |
| WHLM | -0.37% | $19.81M | -14.82% | 0.00% |
| RDDT | 0.38% | $27.74B | +364.76% | 0.00% |
| EG | -0.40% | $16.55B | -5.60% | 1.93% |
| FATBB | -0.55% | $75.27M | -12.35% | 12.73% |
| AJG | -0.58% | $66.36B | +20.50% | 0.77% |
| GIS | 0.62% | $35.60B | -1.16% | 3.70% |
| PRT | 0.69% | $48.51M | -17.78% | 10.36% |
| IBN | 0.70% | $105.19B | +34.81% | 0.78% |
| X | 0.72% | $9.12B | +16.74% | 0.51% |
| CNK | 0.75% | $3.95B | +131.51% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BTCT | -17.09% | $58.86M | +395.83% | 0.00% |
| MNOV | -16.15% | $98.09M | +5.26% | 0.00% |
| MCK | -13.99% | $79.75B | +37.34% | 0.41% |
| OXBR | -12.58% | $19.24M | +183.49% | 0.00% |
| CYD | -12.13% | $384.48M | -0.79% | 4.00% |
| HUSA | -9.90% | $18.58M | -19.77% | 0.00% |
| PULM | -8.79% | $22.32M | +230.27% | 0.00% |
| CHD | -7.21% | $27.50B | +19.29% | 1.01% |
| PGR | -6.88% | $154.33B | +62.01% | 0.44% |
| COR | -6.17% | $48.41B | +23.04% | 0.84% |
| GPCR | -6.13% | $1.72B | -41.41% | 0.00% |
| VIRT | -5.63% | $3.25B | +113.85% | 2.55% |
| ACGL | -5.29% | $37.09B | +20.63% | 0.00% |
| STG | -2.65% | $35.47M | +5.43% | 0.00% |
| MNR | -2.59% | $1.70B | -6.89% | 15.55% |
| CARV | -2.56% | $8.33M | -20.10% | 0.00% |
| NEUE | -2.49% | $41.96M | -33.09% | 0.00% |
| VHC | -2.36% | $18.68M | -40.78% | 0.00% |
| LPLA | -2.11% | $24.20B | +42.81% | 0.37% |
| MPAA | -2.10% | $137.97M | -29.66% | 0.00% |
ETF's related to CRBU
News
Yahoo
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences: Citi's 2024 Global Healthcare Conference, Miami, FL December 3, 2024, panel at 2:30 PM ESTPanel title: Cell therapies in autoimmune disordersWebcast 7th Annual Evercore ISI HealthCONx Confe
Yahoo
Shareholders will be ecstatic, with their stake up 21% over the past week following Caribou Biosciences, Inc. 's...
Yahoo
Caribou Biosciences ( NASDAQ:CRBU ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.02m (down 91% from...
Yahoo
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of 13.64% and 39.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data report planned for H1 2025 -- -- Continuing dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in r/r MM with higher lymphodepletion regimen following observations of efficacy; dose escalation d
Yahoo
We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Caribou Biosciences, Inc. (NASDAQ:CRBU) stands against other most promising gene editing stocks to buy according to hedge funds. The pharmaceutical industry remains a hub of […]
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.